[HTML] elifesciences.org

[HTML][HTML] An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - Elife, 2021 - elifesciences.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …
被引用次数：164 相关文章 网页快照

An open label trial of anakinra to prevent respiratory failure in COVID-19.

E Kyriazopoulou, P Panagopoulos, S Metallidis… - 2021 - cabidigitallibrary.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - 2021 - agris.fao.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …
[PDF] academia.edu

[PDF][PDF] An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - academia.edu
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR! 6 ng/ml …

An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods A total of 130 patients with suPAR≥ 6 ng/ml …
[PDF] sepsis.gr

[PDF][PDF] An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - hssg.sepsis.gr
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR! 6 ng/ml …
[PDF] sepsis.gr

[PDF][PDF] An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - sepsis.gr
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR! 6 ng/ml …

An open label trial of anakinra to prevent respiratory failure in COVID-19.

E Kyriazopoulou, P Panagopoulos, S Metallidis… - Elife, 2021 - europepmc.org
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …
[HTML] nih.gov

[HTML][HTML] An open label trial of anakinra to prevent respiratory failure in COVID-19

E Kyriazopoulou, P Panagopoulos, S Metallidis… - eLife, 2021 - ncbi.nlm.nih.gov
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

An open label trial of anakinra to prevent respiratory failure in COVID-19.

E Kyriazopoulou, P Panagopoulos, S Metallidis… - eLife, 2021 - search.ebscohost.com
Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …